[EN] SELECTIVE ANDROGEN RECEPTOR COVALENT ANTAGONISTS (SARCAS) AND METHODS OF USE THEREOF<br/>[FR] ANTAGONISTES COVALENTS DU RÉCEPTEUR DES ANDROGÈNES SÉLECTIFS (SARCAS) ET MÉTHODES D'UTILISATION ASSOCIÉES
申请人:UNIV TENNESSEE RES FOUND
公开号:WO2021173731A1
公开(公告)日:2021-09-02
This invention relates to selective androgen receptor covalent antagonists, synthetic intermediates and by-products, and related compounds, and compositions comprising the same, and uses thereof in treating androgen receptor dependent diseases and conditions such as hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR.
这项发明涉及选择性雄激素受体共价拮抗剂、合成中间体和副产物,以及相关化合物、包含这些化合物的组合物,以及在治疗雄激素受体依赖性疾病和病状中的用途,如前列腺的高增殖,包括前癌变和良性前列腺增生,前列腺癌,晚期前列腺癌,去势耐药前列腺癌,三阴性乳腺癌,其他表达雄激素受体的癌症,雄激素性脱发或其他高雄激素皮肤疾病,肯尼迪病,肌萎缩性侧索硬化症(ALS),腹主动脉瘤(AAA)和子宫肌瘤,以及降低雄激素受体全长(AR-FL)的水平的方法,包括病理性或耐药突变,AR-剪接变体(AR-SV)和AR的病理性多谷氨酸(polyQ)多态性。